Total Payments
$588,126
2024 Payments
$87,438
Companies
25
Transactions
359
Medicare Patients
74
Medicare Billing
$9,409
Payment Breakdown by Category
Consulting$483,547 (82.2%)
Other$63,234 (10.8%)
Travel$20,948 (3.6%)
Research$14,192 (2.4%)
Food & Beverage$6,156 (1.0%)
Education$49.62 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $483,547 | 163 | 82.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $25,270 | 4 | 4.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,760 | 9 | 3.7% |
| Travel and Lodging | $20,948 | 56 | 3.6% |
| Honoraria | $16,204 | 7 | 2.8% |
| Unspecified | $14,192 | 36 | 2.4% |
| Food and Beverage | $6,156 | 81 | 1.0% |
| Education | $49.62 | 3 | 0.0% |
Payments by Type
General
$573,935
323 transactions
Research
$14,192
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Global Blood Therapeutics, Inc. | $150,998 | 42 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $85,684 | 81 | $0 (2022) |
| VERTEX PHARMACEUTICALS INCORPORATED | $75,533 | 35 | $0 (2024) |
| PFIZER INC. | $60,645 | 46 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $51,860 | 46 | $0 (2024) |
| bluebird bio, Inc. | $32,300 | 5 | $0 (2024) |
| Novo Nordisk Health Care AG | $29,467 | 12 | $0 (2024) |
| Novo Nordisk Inc | $27,511 | 14 | $0 (2024) |
| BIOVERATIV THERAPEUTICS INC. | $17,931 | 26 | $0 (2020) |
| Novo Nordisk AS | $9,450 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87,438 | 48 | VERTEX PHARMACEUTICALS INCORPORATED ($26,880) |
| 2023 | $115,005 | 65 | PFIZER INC. ($30,109) |
| 2022 | $103,647 | 54 | Global Blood Therapeutics, Inc. ($56,569) |
| 2021 | $104,575 | 31 | Global Blood Therapeutics, Inc. ($79,960) |
| 2020 | $58,756 | 45 | VERTEX PHARMACEUTICALS INCORPORATED ($14,906) |
| 2019 | $39,760 | 46 | Novartis Pharmaceuticals Corporation ($14,930) |
| 2018 | $69,088 | 53 | Novartis Pharmaceuticals Corporation ($50,279) |
| 2017 | $9,859 | 17 | Bioverativ Therapeutics Inc. ($5,655) |
All Payment Transactions
359 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $3,574.00 | General |
| Category: HEMATOLOGY | ||||||
| 12/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| 12/16/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,460.00 | General |
| 12/10/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Genetically Defined Disease | ||||||
| 12/08/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $6.27 | General |
| Category: Genetically Defined Disease | ||||||
| 12/07/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $42.93 | General |
| Category: Genetically Defined Disease | ||||||
| 12/07/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $5.42 | General |
| Category: Genetically Defined Disease | ||||||
| 11/11/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $277.50 | General |
| Category: Genetically Defined Disease | ||||||
| 11/06/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $8,060.76 | General |
| Category: Genetically Defined Disease | ||||||
| 11/06/2024 | PFIZER INC. | OXBRYTA (Drug) | Travel and Lodging | In-kind items and services | $1,539.38 | General |
| Category: HEMATOLOGY | ||||||
| 11/06/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $679.05 | General |
| Category: HEMATOLOGY | ||||||
| 10/02/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $6.22 | General |
| Category: Genetically Defined Disease | ||||||
| 10/01/2024 | Novo Nordisk Health Care AG | — | Consulting Fee | Cash or cash equivalent | $4,165.00 | General |
| 10/01/2024 | PFIZER INC. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: HEMATOLOGY | ||||||
| 10/01/2024 | Novo Nordisk Health Care AG | — | Travel and Lodging | In-kind items and services | $377.15 | General |
| 09/09/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $80.56 | General |
| Category: Genetically Defined Disease | ||||||
| 09/01/2024 | Novo Nordisk Health Care AG | — | Consulting Fee | Cash or cash equivalent | $2,975.00 | General |
| 08/19/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $4,986.00 | General |
| 08/14/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Genetically Defined Disease | ||||||
| 08/01/2024 | PFIZER INC. | OXBRYTA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VOXELOTOR CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 07/30/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $5,880.00 | General |
| 07/23/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Travel and Lodging | Cash or cash equivalent | $5.78 | General |
| Category: Genetically Defined Disease | ||||||
| 07/16/2024 | PFIZER INC. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,260.00 | General |
| Category: HEMATOLOGY | ||||||
| 07/15/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $530.00 | General |
| 06/13/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $0.81 | General |
| Category: Genetically Defined Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $6,170 | 21 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ADAKVEO RESEARCH | Novartis Pharmaceuticals Corporation | $2,181 | 1 |
| VOXELOTOR CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,890 | 3 |
| INCLACUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,058 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $878.00 | 3 |
| VOXELOTOR MULTI PRODUCT INCLACUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $620.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 17 | 23 | $6,670 | $2,496 |
| 2022 | 1 | 21 | 29 | $7,975 | $3,047 |
| 2021 | 1 | 18 | 21 | $5,775 | $2,557 |
| 2020 | 1 | 18 | 21 | $4,305 | $1,309 |
Total Patients
74
Total Services
94
Medicare Billing
$9,409
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 23 | $6,670 | $2,496 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 21 | 29 | $7,975 | $3,047 | 38.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 21 | $5,775 | $2,557 | 44.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 21 | $4,305 | $1,309 | 30.4% |
About Dr. Biree Andemariam, MD
Dr. Biree Andemariam, MD is a Hematology & Oncology healthcare provider based in Farmington, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396935136.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Biree Andemariam, MD has received a total of $588,126 in payments from pharmaceutical and medical device companies, with $87,438 received in 2024. These payments were reported across 359 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($483,547).
As a Medicare-enrolled provider, Andemariam has provided services to 74 Medicare beneficiaries, totaling 94 services with total Medicare billing of $9,409. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Farmington, CT
- Active Since 07/27/2007
- Last Updated 09/26/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1396935136
Products in Payments
- OXBRYTA (Drug) $167,363
- PYRUKYND (Drug) $50,622
- CRIZANLIZUMAB (Biological) $30,250
- SKYSONA (Drug) $28,560
- ADAKVEO (Biological) $25,650
- PROMACTA (Drug) $9,759
- NO PRODUCT DISCUSSED (Drug) $8,568
- HEMLIBRA (Biological) $8,146
- Endari (Drug) $4,850
- LYFGENIA (Drug) $3,740
- Narsoplimab (Drug) $2,800
- SevenFact (Biological) $2,500
- Spectra Optia Apheresis System (Device) $2,375
- NovoSeven RT (Drug) $2,160
- KEYTRUDA (Biological) $1,471
- Quzyttir (Drug) $1,110
- Jivi (Drug) $1,088
- Non-Covered Product (Drug) $1,056
- ENDARI (Drug) $303.76
- ALPROLIX (Drug) $125.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Farmington
Aakash Desai, Mbbs, MBBS
Hematology & Oncology — Payments: $42,232
Hematology & Oncology $42,232
Dr. Sardar Imam, M.d, M.D
Hematology & Oncology — Payments: $37,197
Hematology & Oncology $37,197
Ankit Anand, M.d, M.D
Hematology & Oncology — Payments: $16,232
Hematology & Oncology $16,232
Dr. Jeffrey Neidhart, Md, MD
Hematology & Oncology — Payments: $13,104
Hematology & Oncology $13,104
Susan Tannenbaum, Md, MD
Hematology & Oncology — Payments: $6,994
Hematology & Oncology $6,994
Robert Bona, Md, MD
Hematology & Oncology — Payments: $4,937
Hematology & Oncology $4,937